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Abstract
Background: The esophageal carcinoma related gene 4 (ECRG4) was initially identified and cloned from human
normal esophageal epithelium in our laboratory (GenBank accession no.AF325503). ECRG4 has been described as a
novel tumor suppressor gene associated with prognosis in esophageal squamous cell carcinoma (ESCC).
Methods: In this study, binding affinity assay in vitro and co-immunoprecipitation experiment in vivo were utilized
to verify the physical interaction between ECRG4 and transmembrane protease, serine 11A (TMPRSS11A, also
known as ECRG1, GenBank accession no. AF 071882). Then, p21 protein expression, cell cycle and cell proliferation
regulations were examined after ECRG4 and ECRG1 co-transfection in ESCC cells.
Results: We revealed for the first time that ECRG4 interacted directly with ECRG1 to inhibit cancer cell proliferation
and induce cell cycle G1 phase block in ESCC. Binding affinity and co-immunoprecipitation assays demonstrated
that ECRG4 interacted directly with ECRG1 in ESCC cells. Furthermore, the ECRG4 and ECRG1 co-expression
remarkably upregulatd p21 protein level by Western blot (P < 0.001), induced cell cycle G1 phase block by flow
cytometric analysis (P < 0.001) and suppressed cell proliferation by MTT and BrdU assay (both P < 0.01) in ESCC
cells.
Conclusions: ECRG4 interacts directly with ECRG1 to upregulate p21 protein expression, induce cell cycle G1 phase
block and inhibit cancer cells proliferation in ESCC.
Background
Esophageal carcinoma ranks 7
th and 6
th in terms of can-
cer incidence and mortality rate worldwide, respectively
[1]. Moreover, nearly 50% of esophageal carcinoma
cases in the world occurred in China [2]. Esophageal
squamous cell carcinoma (ESCC), which is the most
common histological subtype, accounts for ~90% of all
esophageal cancers diagnosed in China each year.
Despite advances in clinical comprehensive treatment,
ESCC prognosis remains poor due to its diffuse and
invasive nature. To date, the molecular pathogenesis of
ESCC is still unclear [3,4]. At present, the focus of biol-
ogy studies is transitioning from the cloning of novel
genes to characterizing the function of the protein
product. As a result, a major research effort has been
directed at identifying the function of novel specific eso-
phageal cancer related genes and elucidating the rele-
vant molecular interactions of protein products which
may play critical roles in ESCC.
The ECRG4 gene (GenBank accession no. AF 325503)
was initially identified and cloned in our laboratory from
human normal esophageal epithelium [5-7]. Either ECRG4
RNA or ECRG4 protein was an independent prognostic
factor for ESCC, and the low expression of ECRG4 gene in
patients with ESCC was associated with poor prognosis
[8,9]. Furthermore, ECRG4 overexpression in ESCC cells
inhibited tumor cells growth and invasion [9,10]. And
recent studies showed that ECRG4 might be involved in
the development of multi-tumors [11-13].
In the present study, we further explored the func-
tional interaction between ECRG4 and transmembrane
protease, serine 11A (TMPRSS11A, also known as
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press cell growth in ESCC.
Methods
Construction of eukaryotic expression vector and
transfection
The coding region of ECRG4 or ECRG1 cDNA was sub-
cloned into constitutive mammalian expression vector
pcDNA3.1 (Invitrogen). The cDNA was then fully
sequenced to ensure that no mutation was introduced
during the PCR amplification. The resulting plasmid
construct was named pcDNA3.1-His-ECRG4 and
pcDNA3.1-FLAG-ECRG1. The human esophageal squa-
mous cell line EC9706 was established and studied by
Han et al [14]. EC9706 cells were transfected with
pcDNA3.1-His-ECRG4 or pcDNA3.1-FLAG-ECRG1
using lipofectamine™ 2000 (Invitrogen, CA), according
to the manufacturer’s protocol.
Produce and purification of recombinant ECRG4 protein
The ECRG4 cDNA was excised from pGEM-T-ECRG4
and subcloned into the pET30a (+) plasmid, producing
an inducible expression vector coding for His-tagged
ECRG4 soluble protein. Subsequently, the recombinant
plasmids were transformed into Escherichia coli BL21
(DE3) cells to produce N-terminal His-tagged soluble
ECRG4 protein. Fusion protein expression in Escherichia
coli BL21 cells was induced with 0.3 mM isopropyl-D-
thiogalactopyranoside (IPTG), and the protein was puri-
fied by affinity chromatography with nickel-nitrilotriace-
tic acid (Ni-NTA) resin (Novagen), according to the
manufacturer’s protocol. The purified fusion protein was
dialyzed in phosphate-buffered saline (PBS; 0.1 M
sodium phosphate and 0.15 M sodium chloride
[pH 7.4]) to remove the denaturant [9].
Western blot analysis
Whole-cell lysates of EC9706 cells were prepared by
incubating cells in RIPA buffer (1% NP-40; 0.5% sodium
deoxycholate; 0.1% SDS; 50 mM Tris-HCl [pH 7.5]) con-
taining protease inhibitors. Cell lysates were centrifuged
at 10,000 g for 10 minutes at 4°C. The supernatant was
collected, and the protein concentration was measured
using the BCA™ Protein Assay Kit (Pierce). Proteins
(40 ug) in cell lysates or culture media were separated by
10-15% SDS-polyacrylamide gel electrophoresis and
transferred onto PVDF membrane. The membranes were
b l o c k e di nT B S T( 0 . 2MN a C l ;1 0m MT r i sp H 7 . 4 ;0 . 2 %
Tween20)/5% skim milk for 2 hours at room temperature
and then incubated with primary antibodies in TBST/5%
skim milk. The primary antibodies used for Western blot
analysis were monoclonal mouse anti-His (1:4000),
monoclonal mouse anti-FLAG (1:4000), polyclonal rabbit
anti-p21 (1:4000) and monoclonal mouse anti-b-actin
(1:4000). The membranes were then washed three times
with TBST, followed by incubation with horseradish per-
oxidase-conjugated secondary antibody (1:4000) in
TBST/5% skim milk. Bound antibody was visualized
using ECL detection reagent.
Cell proliferation assays
Cell growth and viability were evaluated by using MTT and
BrdU assays, respectively. For MTT assay, the transfected
cells were seeded into 96-well plates (1.5 × 10
3 cells/well).
After culturing for various durations, cell proliferation was
evaluated by thiazolyl blue tetrazolium bromide (MTT)
assay, according to the manufacturer’s protocol (Sigma-
Aldrich Co., St. Louis, MO, USA). In brief, 10 μlM T Ts o l u -
tion (5 mg/ml) was added to each well, then the cells were
cultured for another 4 hours at 37°C, and 100 μlD M S O
was added to each well and mix vigorously to solubilize
colored crystals produced within the living cells. The absor-
bance at 570 nm was measured by using a multi-well scan-
ning spectrophotometer Victor 3. For the BrdU assay, the
transfected cells were seeded into 96-well plates (1 × 10
5
cells/well). After transfection for two days, the BrdU assay
(BrdU cell proliferation ELISA, Roche) was carried out
according to the manufacture’s instructions.
Flow cytometric analysis of cell cycle
The transfected cells were seeded at a density of 10
6
cells/100-mm dish in RPMI-1640 medium with 10%
FBS for 48 hours. Then cells were washed with ice-cold
PBS, harvested and fixed in 70% ethanol for 30 minutes.
Cells were treated with RNase A and stained with
25 μg/ml propidium iodide (PI). Samples were analyzed
using a FACScan flow cytometer (Becton Dickinson),
according to the manufacturer’s protocol. Experiments
were performed three times in triplicate.
Binding affinity assay
Recombinant purified His-ECRG4 protein was coated on
96-well microtiter plates (5 μg per well) followed by
bovine serum albumin blocking. The whole-cell lysates
of EC9706 cells with FLAG-ECRG1 transfection was
then added to the wells and incubated for 2 h. After
washing, anti-FLAG or anti- Miz-1 antibody was added
to the wells and incubated for 30 min at 37°C. Horse-
radish peroxidase-conjugated secondary antibody (Santa
Cruz, CA) was added to the wells and incubated for
20 min at 37°C. After incubation, the substrate o-pheny-
lenediamine dihydrochloride was added to the wells, and
the colored reaction product was quantified using a
microplate reader at 490 nm [15].
Co-immunoprecipitation
Immunoprecipitation and Western blot analysis was
performed according to the standard protocol (Sigma).
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ECRG4 (10 μg) and pcDNA3.1-FLAG-ECRG1 (3.3 μg)
or with control vectors pcDNA3.1 (10 μg) in 10 cm
dishes using Lipofectamine™2000 (Invitrogen, CA).
Two days after transfection, cells were solubilized with
1 ml of lysis buffer (50 mM Tris-HCl [pH7.5], 150 mM
NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate)
(Roche) on ice for 30 minutes. Insoluble materials were
removed by centrifugation for 20s at 12,000 g at 4°C.
The supernatant was collected and the protein concen-
tration was measured by Bradford method to be
adjusted to a final concentration of 1 mg/ml. The super-
natant was precleared with Protein G (Roche) for 3 h at
4°C. Then 500 μl of lysate was incubated with anti-His
or anti-FLAG antibody coupled to protein G-Sepharose
beads overnight at 4°C with gentle rotation. The beads
were washed with wash buffer (Wash 1: 50 mM Tris-
HCl (pH7.5), 150 mM NaCl, 1% NP40, 0.5% sodium
deoxycholate; Wash 2: 50 mM Tris-HCl [pH7.5], 500
mM NaCl, 0.1% NP40, 0.05% sodium deoxycholate;
Wash 3: 10 mM Tris-HCl [pH7.5], 0.1% NP40, 0.05%
sodium deoxycholate). The immunocomplex retained on
the beads were eluted in 2× Laemmli buffer (20%
glycerol, 2%SDS, 250 mM Tris pH6.8, 10% b-mercap-
toethanol and 0.1% bromophenol blue), boiled and
microcentrifuged. Supernatant proteins were subjected
to 12% SDS-polyacrylamide gel electrophoresis, and
immunoblot analysis for anti-FLAG or anti-His were
performed as described above.
Statistical analysis
All statistical analysis was performed with the SPSS sta-
tistical program (version 13.0). P < 0.05 was considered
statistically significant.
Results
ECRG4 bind to ECRG1 in vitro
Our previous results demonstrated that both ECRG4
and ECRG1 inhibited cell proliferation and induced cell
cycle G1 phase block in ESCC. Furthermore, online
bioinformatics analysis database Swiss-Prot predicted
that ECRG4 could potentially bind to ECRG1 by pro-
tein-protein interaction. Therefore, we speculated that
the tumor suppressor genes ECRG4 and ECRG1 might
interact physically in ESCC. To explore this possibility,
binding affinity assay was performed to test the interac-
tion between ECRG4 and ECRG1 proteins. Recombinant
His-ECRG4 protein was precoated into the wells of
96-well plate and incubated with the total protein
from EC9706/pcDNA3.1-FLAG-ECRG1 or EC9706/
pcDNA3.1-FLAG cells. Bound protein was detected by
anti-FLAG antibody. As the control for background pro-
tein binding, bovine serum albumin was coated into the
wells of 96-well plate and incubated with PBS. The
FLAG-ECRG1 protein exhibited binding to recombinant
His-ECRG4 protein (Figure 1). And no detectable bind-
ing of Miz-1, an interaction partner of ECRG1, to His-
ECRG4 was observed.
ECRG4 interacted directly with ECRG1 in vivo
To investigate whether the interaction between ECRG4
and ECRG1 in ESCC cells occurred in vivo, the co-immu-
noprecipitation assay was utilized to verify the possibility.
And in order to get a better understanding of the physical
association of ECRG4 and ECRG1, the ECRG1 and
ECRG4 null ESCC cell line EC9706 was utilized to be
transfected with ECRG1 and ECRG4 gene, respectively.
The FLAG-ECRG1 or His-ECRG4 protein was detected in
EC9706/pcDNA3.1-FLAG-ECRG1, EC9706/pcDNA3.1-
His-ECRG4, and EC9706/pcDNA3.1-His-ECRG4+FLAG-
ECRG1 cells, respectively (Figure 2A). FLAG tagged
ECRG1 protein was transiently co-expressed in EC9706
cells together with His-ECRG4. As negative control,
pcDNA3.1-FLAG empty vector replaced pcDNA3.1-
FLAG-ECRG1 in EC9706 cells. The cell lysates with high
protein expression of His-ECRG4 and FLAG-ECRG1
detected by immunoblotting were then immunoprecipi-
tated with anti-FLAG monoclonal antibody. Immunopre-
cipitated proteins were separated by SDS-PAGE and
immunoblotted with anti-His monoclonal antibody. The
results showed that His-ECRG4 was present in the immu-
noprecipitates from cells expressing both FLAG-ECRG1
and His-ECRG4 proteins, but not in the control group
(Figure 2B). In the inverse experiment, pcDNA3.1-His
empty vector replaced pcDNA3.1-His-ECRG4 as negative
control. The protein lysates were immunoprecipitated
with anti-His antibody and immunoblotted with anti-
FLAG antibody. Consistently, the results demonstrated
that the immunoprecipitates contained FLAG-ECRG1
protein when the cells were co-transfected with
pcDNA3.1-His-ECRG4 and pcDNA3.1-FLAG-ECRG1
genes, but not in the control group (Figure 2C). Alto-
gether, the co-immunoprecipitation assays in vivo sup-
ported the interaction between ECRG4 and ECRG1
proteins in ESCC cells.
ECRG4 and ECRG1 co-expression increased p21
expression
The interaction between ECRG4 and ECRG1 indicated
that the two proteins might be involved in same physio-
logical process. So we examined the effect of ECRG4
and ECRG1 co-transfection in EC9706 cells on cell cycle
G1 phase regulation gene p21 expression. The EC9706
cells were transfected with ECRG1 and ECRG4 genes,
alone or combined, and p21 expression was analyzed by
Western blot assay. The result showed that either
ECRG4 or ECRG1 transfection could upregulat the p21
expression level. Furthermore, the co-transfection of
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tion effect in EC9706 cells (P < 0.001) (Figure 3). The
results suggested that the ECRG4 and ECRG1 co-
expression enhanced p21 upregulation in ESCC cells.
ECRG4 and ECRG1 co-expression reinforced cell cycle G1
phase block
Cell cycle examination was carried out by flow cyto-
metric analysis in an attempt to explore the effect of p21
upregulatin induced by ECRG4 and ECRG1 co-expres-
sion. The result suggested that either ECRG4 or ECRG1
expression could arrest ESCC cells at the G1/S check-
point and delay cell cycle into S phase. Furthermore, the
ECRG4 and ECRG1 co-expression reinforced the cell
cycle G1 phase block effect (P < 0.001) (Table 1). Conse-
quently, ECRG4 and ECRG1 co-expression slowed down
cell cycle progression and enhanced cell cycle G1 phase
block in ESCC cells.
ECRG4 and ECRG1 co-expression inhibited tumor cell
growth
To further evaluate the inhibitory effect of ECRG4 and
ECRG1 co-expression on cancer cell growth, the MTT
and BrdU assays were utilized to examine cell viability and
proliferation. The proliferation of EC9706 cells with either
ECRG4 or ECRG1 transfection were inhibited compared
with the control cells. Furthermore, the ECRG4 and
ECRG1 co-transfection significantly reinforced the cell
proliferation inhibition effect, as assessed by the BrdU
assay (P < 0.01) (Figure 4). Moreover, cell growth curves
also demonstrated that ECRG4 and ECRG1 co-transfec-
tion significantly slowed down cancer cells growth by
Figure 1 The interaction between ECRG4 and ECRG1 was examined by binding affinity assay in vitro. FLAG-ECRG1 from EC9706/
pcDNA3.1-FLAG-ECRG1 cells was bound to recombinant His-ECRG4 protein which had been pre-coated on the plate. The absorbance values of
the wells (column 6) were significantly higher than those of controls (P < 0.001). And no detectable binding of Miz-1, an interaction partner of
ECRG1, to His-ECRG4 was observed. *, P < 0.001, compared with EC9706/pcDNA3.1-FLAG cells.
Li et al. BMC Cancer 2011, 11:52
http://www.biomedcentral.com/1471-2407/11/52
Page 4 of 7MTT assay (P < 0.01) (Figure 5). The results indicated that
ECRG4 and ECRG1 co-expression significantly enhanced
the growth-suppressing effect in ESCC cells.
Discussion and Conclusions
ESCC is a highly invasive and clinically challenging can-
cer in China. Until now, its molecular basis remains
poorly understood. And ECRG4 gene is highly conserved
among various species, suggesting an important role for
ECRG4 in eukaryotic cells. However, its exactly biological
function in carcinogenesis is still unclear. Our previous
study demonstrated that ECRG4 is a novel tumor sup-
pressor gene in ESCC. ECRG4 gene promoter hyper-
methylation accounted for decreased expression in
ESCC, and the low expression of ECRG4 protein in
patients with ESCC was associated with poor prognosis
[7,9]. These findings were also supported by similar stu-
dies of other research groups [8,11,12]. Furthermore,
restoration of ECRG4 expression in tumor cells inhibited
cell growth and invasion [9,10,13]. And ECRG4 was also
involved in cell differentiation and senescence [16-19].
ECRG1 (GenBank accession no. AF 071882) was also
the candidate tumor suppressor gene in ESCC. The
ECRG1 290 Arg/Gln and Gln/Gln genotypes were asso-
ciated with increased risk for squamous cell carcinoma,
Table 1 ECRG4 and ECRG1 induced cell cycle G1 phase
block
Group G1 S G2/M
EC9706/pcDNA3.1 60.1 ± 2.11 24.5 ± 1.53 15.4 ± 1.67
EC9706/pcDNA3.1-ECRG4 70.6 ± 1.62 15.7 ± 1.35 13.7 ± 0.87
EC9706/pcDNA3.1-ECRG1 66.9 ± 1.58 19.6 ± 1.41 13.5 ± 1.03
EC9706/pcDNA3.1-ECRG4+ECRG1
# 75.8 ± 1.82 11.3 ± 1.37 12.9 ±1.16
# P < 0.001, compared with EC9706/pcDNA3.1.
Figure 2 The interaction between ECRG4 and ECRG1 was
verified by co-immunoprecipitation assay in vivo. (A) Detection
of ECRG4 and ECRG1 protein expression in transfected cells
(pcDNA3.1, pcDNA3.1-His-ECRG4, pcDNA3.1-FLAG-ECRG1 and
pcDNA3.1-His-ECRG4+FLAG-ECRG1) by Western blot. FLAG-ECRG1 or
His-ECRG4 protein was detectable in EC9706/pcDNA3.1-FLAG-ECRG1
or EC9706/pcDNA3.1-His-ECRG4 cells, respectively, and both in
EC9706/pcDNA3.1-His-ECRG4+pcDNA3.1-FLAG-ECRG1 cells. (B)
EC9706 cells, transiently transfected with FLAG-ECRG1 and His-
ECRG4, were immunoprecipitated by anti-FLAG antibody and
detected by anti-His antibody. As negative control, pcDNA3.1-FLAG
empty vector replaced FLAG-ECRG1. Protein lysates of EC9706/FLAG-
ECRG1+His-ECRG4 (Lane 1) and EC9706/FLAG+ His-ECRG4 (Lane 2)
were immunoprecipitated by anti-FLAG antibody and visualized by
anti-His antibody. The rabbit IgG antibody was used as negative
control, and it showed no non-specific binding of ECRG1 with IgG.
(C) EC9706 cells, transiently transfected with FLAG-ECRG1 and His-
ECRG4, were immunoprecipitated by anti-His antibody and detected
by anti-FLAG antibody. As negative control, pcDNA3.1-His empty
vector replaced His-ECRG4. Protein lysates of EC9706/FLAG-ECRG1
+His-ECRG4 (Lane 1) and EC9706/FLAG-ECRG1+His (Lane 2) were
immunoprecipitated by anti-His antibody and visualized by anti-
FLAG antibody. The rabbit IgG antibody was used as negative
control, and it showed no non-specific binding of ECRG4 with IgG.
Figure 3 Effect of ECRG4 and ECRG1 co-expression on p21 protein level. Representative photo (left) and statistic plot (right) of
relative protein expression ratios in EC9706/pcDNA3.1, EC9706/pcDNA3.1-ECRG1, EC9706/pcDNA3.1-ECRG4 and EC9706/pcDNA3.1-
ECRG4+ECRG1 cells. Analysis of cell’s total proteins by Western blot showed that p21 protein expression was significantly increased in EC9706/
pcDNA3.1-ECRG4+ECRG1 cells compared with in EC9706/pcDNA3.1 cells (P < 0.001). *, P < 0.001, compared with EC9706/pcDNA3.1 cells.
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vious results demonstrated that overexpression of
ECRG1 gene in ESCC cells inhibited tumor cells growth
in vitro and in vivo [23,24]. Furthermore, ECRG1 could
induce cell cycle G1 phase arrest and cell senescence
through interaction with Miz-1 protein in ESCC cells
[25-27]. These findings indicated that ECRG1 played an
important role in controlling the gene expression
involved in cell cycle G1 phase regulation and cell pro-
liferation in ESCC.
O u rd a t ad e m o n s t r a t e dt h a tE C R G 4c o u l da l s oc a u s e
cell cycle G1 phase block by inducing p21 upregulation
in ESCC cells [10]. And Bioinformatics analysis indi-
cated that ECRG4 might be directly associated with
ECRG1 by protein-protein interaction. In this study,
binding affinity assay also demonstrated that ECRG4
could bind to ECRG1. Therefore, we reasoned that
ECRG4 might interact with ECRG1 to co-regulate cell
cycle and cell proliferation. As the binding affinity assay
provided only potential interaction, we further per-
formed co-immunoprecipitation assay in vivo to confirm
the biological interaction between ECRG1 and ECRG4
in ESCC cells. In order to get a better understanding of
the association of ECRG1 and ECRG4 on cell cycle and
cell proliferation, as well as various physiological pro-
cesses, the ECRG1 and ECRG4 null EC9706 cell line
was utilized to examine the effect. The results showed
that cell cycle G1 phase block and cell proliferation inhi-
bition effects were remarkably enhanced by ECRG1 and
ECRG4 co-expression in ESCC cells. It indicated that
ECRG1 and ECRG4 might act as co-functional proteins
in cell cycle and growth regulation in ESCC.
The cell cycle alteration plays a major role in carcino-
genesis. Once the cell cycle regulation balance was bro-
ken, it might result in tumorigenesis. Evidence has
revealed that many oncogenes and tumor suppressor
genes are directly involved in regulation of cell cycle
events [28]. The p21 and p16 genes, critical cyclin-
dependent kinase inhibitors, were functionally relevant
to the regulation of cell cycle G1 phase. In the present
research, we observed that ECRG4 and ECRG1 co-
expression significantly induced cell cycle G1 phase
block through upregulating p21 expression in ESCC
cells. However, there was no significant change of p16
expression level in ESCC cells (data not shown). Based
on our data, we speculated that ECRG1 and ECRG4
might co-regulate p21 expression to control cell cycle
progression in ESCC. It is well known that p21 upregu-
lation is able to block the cell cycle at G1 phase [29,30].
So the p21 overexpression induced by ECRG4 and
ECRG1 co-expression could be the possible molecular
mechanism for cell cycle G1 phase block and growth
suppression in ESCC.
Taken together, we discovered for the first time that
ECRG4 directly interacted with ECRG1 to upregulate
p 2 1e x p r e s s i o n ,i n d u c ec e l lc y c l eG 1p h a s eb l o c ka n d
inhibit cancer cells proliferation in ESCC. Our study
implied that the interaction of ECRG4 with ECRG1
could be an important therapeutic target for ESCC.
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